Takeda Pharmaceutical (TAK) reported fiscal Q3 core earnings Thursday of 132 Japanese yen ($0.84) per basic share, down from 150 yen a year earlier.
Four analysts polled by FactSet expected 124 yen.
Revenue for the quarter ended Dec. 31 was 1.144 trillion yen, up from 1.111 trillion yen a year earlier.
Analysts surveyed by FactSet expected 1.138 trillion yen.
The company now expects core earnings guidance for the fiscal year ended March 31 to be 507 yen per share, compared with its prior guidance of 456 yen set on Oct. 31, 2024.
Analysts surveyed by FactSet expect 480 yen.
The company now expects revenue for the fiscal year of 4.59 trillion yen, compared with its prior guidance of 4.48 trillion yen. A single analyst polled by FactSet expects 4.562 trillion yen.
Shares of the company rose 3.5% in premarket activity Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.